Abstract

In July production of etretinate (Tigason – Roche) ceased and in its place the manufacturer is promoting acitretin (Neotigason – Roche). Like etretinate, acitretin is marketed for the treatment in hospital of patients with severe, extensive, resistant psoriasis and for palmoplantar pustular psoriasis, severe congenital ichthyosis or severe Darier’s disease (keratosis follicularis). Does acitretin offer any advantage?